» Articles » PMID: 19368274

[Influence of Dexamethasone on Appetite and Body Weight in Lung Cancer Patients]

Overview
Journal Med Pregl
Specialty General Medicine
Date 2009 Apr 17
PMID 19368274
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Anorexia and cachexia are the most common symptoms in cancer patients. They increase morbidity and mortality among cancer patients as well as complications of surgery, radiotherapy and chemotherapy. The most common drugs for treatment of cancer cachexia are corticosteroids and megestrol acetate.

Material And Methods: The purpose of this study was to determine the influence of dexamethasone on appetite loss and weight loss in lung cancer patients treated with chemotherapy. Group A (30 patients) was treated with cisplatin, etoposide and standard supportive therapy, while group B (30 patients) received, in addition to this treatment, dexamethasone in the dose of 8 mg intravenously per day (1-3 day of chemotherapy).

Results: There was a statistically significant difference in appetite loss between two groups after the second chemotherapy cycle favouring group A. The analysis of weight loss showed a statistically significant difference between two groups after both chemotherapy cycles, once again in favour of group A. Concerning the impovement of appetite and weight gain, there was no statistically significant difference between two groups after both chemotherapy cycles.

Discussion: Many double-blind randomized controlled studies showed beneficial symptomatic effect of corticosteroids in cancer cachexia, especially on the improvement of appetite, food intake and performance status. In most of the studies the weight gain was not recorded The most effective type of corticosteroids, dose and route of administration have not been established.

Conclusion: Dexamethasone significantly decreases appetite loss and weight loss in lung cancer patients treated with chemotherapy, while it has no influence on appetite impovement and weight gain.

Citing Articles

[Research Progress of Pharmacological Therapy and Nutritional Support for Cachexia 
in Lung Cancer Patients].

Wang J, Jia W, Li D, Song Y, Sun N, Yang K Zhongguo Fei Ai Za Zhi. 2022; 25(6):420-424.

PMID: 35747921 PMC: 9244501. DOI: 10.3779/j.issn.1009-3419.2022.101.21.


Drug repositioning in non-small cell lung cancer (NSCLC) using gene co-expression and drug-gene interaction networks analysis.

MotieGhader H, Tabrizi-Nezhadi P, Paskeh M, Baradaran B, Mokhtarzadeh A, Hashemi M Sci Rep. 2022; 12(1):9417.

PMID: 35676421 PMC: 9177601. DOI: 10.1038/s41598-022-13719-8.


Integrated Environmental and Genomic Analysis Reveals the Drivers of Local Adaptation in African Indigenous Chickens.

Gheyas A, Vallejo-Trujillo A, Kebede A, Lozano-Jaramillo M, Dessie T, Smith J Mol Biol Evol. 2021; 38(10):4268-4285.

PMID: 34021753 PMC: 8476150. DOI: 10.1093/molbev/msab156.


Use of non-opioid analgesics as adjuvants to opioid analgesia for cancer pain management in an inpatient palliative unit: does this improve pain control and reduce opioid requirements?.

Shinde S, Gordon P, Sharma P, Gross J, Davis M Support Care Cancer. 2014; 23(3):695-703.

PMID: 25168780 DOI: 10.1007/s00520-014-2415-9.


Optimal management of cancer anorexia-cachexia syndrome.

Argiles J, Olivan M, Busquets S, Lopez-Soriano F Cancer Manag Res. 2010; 2:27-38.

PMID: 21188094 PMC: 3004581. DOI: 10.2147/cmar.s7101.